Cytokinetics' New Rally Pauses On Buyer Exhaustion

Cytokinetics seemed to catch the attention of biotech buyers this year, as demonstrated by the fact that YTD gains on CYTK are already close to 58% despite a lack of any major press releases from Cytokinetics since their transfer from the NASDAQ Global Market to the NASDAQ Capital Market as described in a press release from December 18th, 2012.

http://seekingalpha.com/article/1121381-cytokinetics-new-rally-pauses-on-buyer-exhaustion?source=feed